Welcome to our dedicated page for KIORA PHARMACEUTICALS SEC filings (Ticker: KPRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Kiora Pharmaceuticals filings document a clinical-stage ophthalmology issuer focused on small-molecule programs for retinal disease. Current disclosures cover results of operations and financial condition, research-and-development progress for KIO-301 and KIO-104, collaboration reimbursements, and clinical or regulatory updates tied to the company’s development pipeline.
Material-event reports also record securities purchase agreements, common stock, pre-funded warrants and Tranche A warrants issued in private placements, along with executive changes. Proxy materials address board governance, executive compensation, equity awards, shareholder voting matters and related risk-factor disclosures for a Nasdaq-listed Delaware corporation.
Nantahala Capital Partners reported beneficial ownership of 189,705 shares of Kiora Pharmaceuticals common stock, representing 5.299% of the outstanding shares as of August 8, 2025. The filing states that 146,533 of those shares may be acquired within 60 days through the exercise of warrants, and Nantahala holds shared voting and dispositive power over the full 189,705 shares while holding no sole voting or dispositive power. The ownership percentage is calculated using 3,433,491 shares outstanding per Kiora's Form 10-Q filed August 8, 2025. The filing includes certifications that the holdings were acquired in the ordinary course of business and not for the purpose of changing or influencing control.
Rosalind Advisors, Rosalind Master Fund L.P. and two affiliated portfolio managers report beneficial ownership of 464,676 shares of Kiora Pharmaceuticals represented by warrants, which the filing treats as issuable Common Stock. The reported position equals 9.9% of the class based on 3,433,491 shares reported by the issuer, and all four reporting persons show 0 sole voting or dispositive power and 464,676 shared voting and dispositive power.
The filing notes these are pre-funded warrants subject to a blocker provision that prevents exercise to the extent it would raise beneficial ownership above 9.99%, so the actual number of Common Shares the reporting persons may hold after applying the blockers is lower than the amounts reported. The reporting parties certify the holdings were acquired in the ordinary course of business and not to influence control of the issuer.
Kiora Pharmaceuticals, Inc. reported via an 8-K that on August 8, 2025 it issued a press release announcing financial results for the quarter ended June 30, 2025 and provided an update on its clinical development progress. The press release is furnished as Exhibit 99.1 and an Inline XBRL cover page is included as Exhibit 104. The filing states that the furnished information, including Exhibit 99.1, is not deemed "filed" under Section 18 and is not incorporated by reference into other Securities Act or Exchange Act filings except where expressly stated.
The report is signed by Melissa Tosca, Chief Financial Officer. No financial line-item figures or clinical data are presented within the 8-K text itself; readers must refer to Exhibit 99.1 for the detailed press release content.
Kiora Pharmaceuticals (KPRX) Q2-25 10-Q highlights:
- No revenue this quarter; prior-year period had $20k and $16.0 million YTD license revenue.
- Operating expenses fell 7% YoY to $2.4 million as higher R&D (+26%) was offset by larger collaboration credits.
- Net loss narrowed slightly to $2.2 million (-$0.54/sh); six-month loss $4.3 million.
- Cash & equivalents $1.0 million; short-term investments $19.6 million; total current assets $24.7 million vs $29.7 million at YE-24. Operating cash burn first half $6.5 million.
- Deferred $1.25 million option fee from Senju for Asian rights to KIO-301; potential total deal value up to $110.8 million.
- Contingent consideration liability $4.6 million.
- Management projects existing funds will finance operations into late-2027.
- 3.43 million shares outstanding; warrant exercises added 0.39 million shares YTD.
Liquidity remains solid, but near-term value hinges on clinical progress and additional partnering.